February 28, 2019 / 4:43 PM / 18 days ago

BRIEF-FDA Approves New Formulation Of Herceptin For Subcutaneous Use

Feb 28 (Reuters) - U.S. Food and Drug Administration:

* FDA APPROVES NEW FORMULATION OF HERCEPTIN FOR SUBCUTANEOUS USE

* U.S. FDA SAYS APPROVED TRASTUZUMAB AND HYALURONIDASE-OYSK INJECTION, HERCEPTIN HYLECTA, FOR SUBCUTANEOUS USE

* U.S. FDA SAYS HERCEPTIN HYLECTA IS A COMBINATION OF TRASTUZUMAB AND HYALURONIDASE FOR THE TREATMENT OF HER2-OVEREXPRESSING BREAST CANCER Source text: (bit.ly/2EmtTEN) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below